{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:36:04Z","timestamp":1791380164603,"version":"4.3.3"},"reference-count":25,"publisher":"Cambridge University Press (CUP)","issue":"7","license":[{"start":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T00:00:00Z","timestamp":1494288000000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Nutr"],"published-print":{"date-parts":[[2017,4,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiotensin-converting enzyme (ACE) inhibitors are important agents in blood pressure (BP) management. It was recently shown that the egg-protein hydrolysate NWT-03 inhibited ACE in Zucker diabetic fatty rats. We therefore designed a dose-finding study to assess the effects of 1, 2 and 5 g NWT-03 on daytime, 36-h, and night-time systolic and diastolic BP (SBP and DBP) in ninety-two generally healthy subjects with normal BP (<jats:italic>n<\/jats:italic>29), high-normal BP (<jats:italic>n<\/jats:italic>34) or mild hypertension (<jats:italic>n<\/jats:italic>29). The study had a cross-over design with six treatment arms (1 g NWT-03 or placebo in period 1 and placebo or 1 g NWT-03 in period 2, 2 g NTW-03 or placebo in period 1 and placebo or 2 g NWT-03 in period 2, or 5 g NTW-03 or placebo in period 1 and placebo or 5 g NTW-03 in period 2). A comparable number of subjects from each BP class were included in each study arm. Duration of both treatments in each arm was 7 d, separated by 5-d wash-out periods. BP was measured with an ambulatory BP monitor before and after the treatments. In mild-hypertensive subjects, 2 g NWT-03 significantly decreased daytime SBP (7\u00b79 mmHg;<jats:italic>P<\/jats:italic>=0\u00b7006), daytime DBP (4\u00b72 mmHg;<jats:italic>P<\/jats:italic>=0\u00b7009), 36-h SBP (6\u00b79 mmHg;<jats:italic>P<\/jats:italic>=0\u00b7015) and 36-h DBP (3\u00b75 mmHg;<jats:italic>P<\/jats:italic>=0\u00b7035) compared with placebo subjects. In addition, in mild-hypertensive subjects, 5 g NWT-03 significantly decreased night-time SBP (14\u00b78 mmHg;<jats:italic>P<\/jats:italic>=0\u00b7008) and night-time DBP (8\u00b74 mmHg;<jats:italic>P<\/jats:italic>=0\u00b7020) compared with that in placebo subjects. To conclude, we found that 2 g NWT-03 lowered daytime and 36-h BP in subjects with mild hypertension, and 5 g NWT-03 lowered night-time BP in subjects with mild hypertension. As no dose\u2013response relationship was evident, these results should be interpreted with care, and additional studies are needed.<\/jats:p>","DOI":"10.1017\/s0007114517000836","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T11:17:19Z","timestamp":1494328639000},"page":"942-950","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":23,"title":["Effects of NWT-03, an egg-protein hydrolysate, on blood pressure in normotensive, high-normotensive and mild-hypertensive men and women: a dose-finding study"],"prefix":"10.1017","volume":"117","author":[{"given":"Jogchum","family":"Plat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Severins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P.","family":"Mensink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2017,5,9]]},"reference":[{"key":"S0007114517000836_ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-006-0051-6"},{"key":"S0007114517000836_ref20","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2009.34"},{"key":"S0007114517000836_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2006.06.005"},{"key":"S0007114517000836_ref13","doi-asserted-by":"publisher","DOI":"10.1089\/jmf.2009.0253"},{"key":"S0007114517000836_ref3","unstructured":"World Health Organization (2017) Raised blood pressure \u2013 situation and trends. http:\/\/www.who.int\/gho\/ncd\/risk_factors\/blood_pressure_prevalence_text\/en\/index.html"},{"key":"S0007114517000836_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.06.007"},{"key":"S0007114517000836_ref23","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000198542.51471.c4"},{"key":"S0007114517000836_ref4","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/00004872-200311000-00002","article-title":"World Health Organization (WHO)\/International Society of Hypertension (ISH) statement on management of hypertension","volume":"21","author":"Whitworth","year":"2003","journal-title":"J Hypertens"},{"key":"S0007114517000836_ref9","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e3181ba0d8a"},{"key":"S0007114517000836_ref11","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200211000-00017"},{"key":"S0007114517000836_ref15","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.18553\/jmcp.2007.13.s8-b.9","article-title":"The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"S0007114517000836_ref7","doi-asserted-by":"publisher","DOI":"10.1079\/BJN2001324"},{"key":"S0007114517000836_ref25","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.178657"},{"key":"S0007114517000836_ref18","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2039"},{"key":"S0007114517000836_ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046781"},{"key":"S0007114517000836_ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-8-34"},{"key":"S0007114517000836_ref1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001057"},{"key":"S0007114517000836_ref24","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199310000-00019"},{"key":"S0007114517000836_ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/6.1.1"},{"key":"S0007114517000836_ref21","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2013.145"},{"key":"S0007114517000836_ref5","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3281fc975a"},{"key":"S0007114517000836_ref14","doi-asserted-by":"publisher","DOI":"10.3390\/nu7010659"},{"key":"S0007114517000836_ref6","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-nutr-010510-103954"},{"key":"S0007114517000836_ref2","doi-asserted-by":"publisher","DOI":"10.1161\/hc4601.099487"},{"key":"S0007114517000836_ref10","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200109011-00004"}],"container-title":["British Journal of Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007114517000836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T10:48:05Z","timestamp":1659005285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007114517000836\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,14]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,4,14]]}},"alternative-id":["S0007114517000836"],"URL":"https:\/\/doi.org\/10.1017\/s0007114517000836","relation":{},"ISSN":["0007-1145","1475-2662"],"issn-type":[{"value":"0007-1145","type":"print"},{"value":"1475-2662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,14]]},"assertion":[{"value":"Copyright \u00a9 The Authors 2017\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}